The potential of biologics for the treatment of asthma (Q38063791)

28 August 2017

1 reference

title

The potential of biologics for the treatment of asthma (English)

1 reference

28 August 2017

0 references

Alessandro Vatrella

2

0 references

author name string

Girolamo Pelaia

series ordinal

1

1 reference

PubMed ID

23197041

28 August 2017

Rosario Maselli

series ordinal

3

1 reference

28 August 2017

1 December 2012

1 reference

Nature Reviews Drug Discovery

28 August 2017

1 reference

28 August 2017

11

1 reference

28 August 2017

958-972

1 reference

28 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3792

28 August 2017

0 references

cites work

A new look at the pathogenesis of asthma

1 reference

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

31 March 2020

1 reference

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

31 March 2020

1 reference

31 March 2020

1 reference

Influence of comorbid conditions on asthma

31 March 2020

1 reference

Costs of asthma according to the degree of severity.

31 March 2020

1 reference

Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol

31 March 2020

1 reference

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

31 March 2020

1 reference

High prevalence of skin test positivity in severe or difficult-to-treat asthma

31 March 2020

1 reference

IgE in allergy and asthma today

31 March 2020

1 reference

The cytokine network in asthma and chronic obstructive pulmonary disease

31 March 2020

1 reference

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma.

31 March 2020

1 reference

Biologic therapies for asthma

31 March 2020

1 reference

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review

31 March 2020

1 reference

Cytokine/anti-cytokine therapy - novel treatments for asthma?

31 March 2020

1 reference

Effect of 17q21 variants and smoking exposure in early-onset asthma

31 March 2020

1 reference

Asthma phenotypes: the evolution from clinical to molecular approaches

31 March 2020

1 reference

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

31 March 2020

1 reference

The Melbourne Asthma Study: 1964-1999.

31 March 2020

1 reference

Severe asthma: from characteristics to phenotypes to endotypes

31 March 2020

1 reference

Innate cells and T helper 2 cell immunity in airway inflammation

31 March 2020

1 reference

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

31 March 2020

1 reference

Lebrikizumab treatment in adults with asthma

31 March 2020

1 reference

A mechanism for the initiation of allergen-induced T helper type 2 responses

31 March 2020

1 reference

Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity

31 March 2020

1 reference

TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway

31 March 2020

1 reference

31 March 2020

Immunobiology of asthma

1 reference

Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo

31 March 2020

1 reference

RANTES in exhaled breath condensate of stable and unstable asthma patients

31 March 2020

1 reference

Requirement for IL-13 independently of IL-4 in experimental asthma

31 March 2020

1 reference

Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

31 March 2020

1 reference

The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation.

31 March 2020

1 reference

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

31 March 2020

1 reference

Th17 immunity in patients with allergic asthma.

31 March 2020

1 reference

Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells

31 March 2020

1 reference

Risk factors of frequent exacerbations in difficult-to-treat asthma

31 March 2020

1 reference

Role of deficient type III interferon-λ production in asthma exacerbations

31 March 2020

1 reference

Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma.

31 March 2020

1 reference

Decreased FOXP3 protein expression in patients with asthma.

31 March 2020

1 reference

Nonatopic Children with Multitrigger Wheezing Have Airway Pathology Comparable to Atopic Asthma

31 March 2020

1 reference

Remodeling in asthma and chronic obstructive lung disease

31 March 2020

1 reference

Noncontractile functions of airway smooth muscle cells in asthma

31 March 2020

1 reference

Early thickening of the reticular basement membrane in children with difficult asthma

31 March 2020

1 reference

Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers

31 March 2020

1 reference

Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study

31 March 2020

1 reference

The effect of age and duration of disease on airway structure in fatal asthma

31 March 2020

1 reference

Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects

31 March 2020

1 reference

Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis

31 March 2020

1 reference

Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge

31 March 2020

1 reference

Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1.

31 March 2020

1 reference

House dust mite-promoted epithelial-to-mesenchymal transition in human bronchial epithelium.

31 March 2020

1 reference

Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis

31 March 2020

1 reference

Cytokines and growth factors in airway remodeling in asthma.

31 March 2020

1 reference

Airway remodeling contributes to the progressive loss of lung function in asthma: an overview

31 March 2020

1 reference

Molecular regulation of mast cell activation

31 March 2020

1 reference

IgE and mast cells in allergic disease

31 March 2020

1 reference

Inhibition of allergic reactions with antibodies to IgE

31 March 2020

1 reference

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

31 March 2020

1 reference

Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors

31 March 2020

1 reference

Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics.

31 March 2020

1 reference

Human airway smooth muscle cells express the high affinity receptor for IgE (Fc epsilon RI): a critical role of Fc epsilon RI in human airway smooth muscle cell function.

31 March 2020

1 reference

Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells

31 March 2020

1 reference

Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma

31 March 2020

1 reference

Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.

31 March 2020

1 reference

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

31 March 2020

1 reference

Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma

31 March 2020

1 reference

Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation

31 March 2020

1 reference

Effects of an antibody to interleukin-5 in a monkey model of asthma

31 March 2020

1 reference

Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor

31 March 2020

1 reference

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

31 March 2020

1 reference

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

31 March 2020

1 reference

Mepolizumab and exacerbations of refractory eosinophilic asthma

31 March 2020

1 reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

31 March 2020

1 reference

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

31 March 2020

1 reference

Reslizumab for Poorly Controlled, Eosinophilic Asthma

31 March 2020

1 reference

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

31 March 2020

1 reference

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma

31 March 2020

1 reference

Anti-interleukin-4 inhibits immunoglobulin E production in a murine model of atopic asthma

31 March 2020

1 reference

Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

31 March 2020

1 reference

Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma

31 March 2020

1 reference

Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma

31 March 2020

1 reference

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

31 March 2020

1 reference

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

31 March 2020

1 reference

Anti-interleukin-4 therapy

31 March 2020

1 reference

Mouse models to evaluate the function of genes associated with allergic airway disease

31 March 2020

1 reference

A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness

31 March 2020

1 reference

Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma

31 March 2020

1 reference

Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma

31 March 2020

1 reference

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

31 March 2020

1 reference

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist

31 March 2020

1 reference

IL-4 induces IL-13-independent allergic airway inflammation.

31 March 2020

1 reference

Targeting interleukin-4 in asthma: lost in translation?

31 March 2020

1 reference

Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor

31 March 2020

1 reference

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

31 March 2020

1 reference

Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide

31 March 2020

1 reference

A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice

31 March 2020

1 reference

Interleukin-13 in asthma pathogenesis.

31 March 2020

1 reference

Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling

31 March 2020

1 reference

Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354).

31 March 2020

1 reference

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

31 March 2020

1 reference

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

31 March 2020

1 reference

Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model.

31 March 2020

1 reference

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

31 March 2020

1 reference

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

31 March 2020

1 reference

Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF).

31 March 2020

1 reference

A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.

31 March 2020

1 reference

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

31 March 2020

1 reference

Evidence of a role of tumor necrosis factor alpha in refractory asthma

31 March 2020

1 reference

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial.

31 March 2020

1 reference

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma.

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

31 March 2020

1 reference

Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma.

31 March 2020

1 reference

IL-23 and Th17 Cells Enhance Th2-Cell–mediated Eosinophilic Airway Inflammation in Mice

31 March 2020

1 reference

Silencing IL-23 expression by a small hairpin RNA protects against asthma in mice

31 March 2020

1 reference

Interleukin-17 regulation: an attractive therapeutic approach for asthma

31 March 2020

1 reference

IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice

31 March 2020

1 reference

Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway

31 March 2020

1 reference

Interleukin-33 induces interleukin-17F in bronchial epithelial cells.

31 March 2020

1 reference

Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells

31 March 2020

1 reference

IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages.

31 March 2020

1 reference

Syk inhibitors as treatment for allergic rhinitis

31 March 2020

1 reference

Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase

31 March 2020

1 reference

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment

31 March 2020

1 reference

Asthma outcomes: biomarkers

31 March 2020

1 reference

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

31 March 2020

1 reference

Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases.

31 March 2020

1 reference

Choosing asthma step-up care

31 March 2020

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

31 March 2020

1 reference

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

31 March 2020

1 reference

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

31 March 2020

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

31 March 2020

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

31 March 2020

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

31 March 2020

1 reference

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.

31 March 2020

1 reference

Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

31 March 2020

1 reference

Italian real-life experience of omalizumab.

31 March 2020

1 reference

Severe asthma and the omalizumab option.

31 March 2020

1 reference

Omalizumab and the risk of malignancy: results from a pooled analysis

31 March 2020

1 reference

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

31 March 2020

1 reference

Severity of asthma: the role of CD25+, CD30+, NF-kappaB, and apoptotic markers

31 March 2020

1 reference

12 December 2020

IL-4 is required to generate and sustain in vivo IgE responses

1 reference

12 December 2020

Humanization of an antibody directed against IgE

1 reference

12 December 2020

Murine model of allergen induced asthma

1 reference

12 December 2020

Omalizumab in the treatment of severe asthma: efficacy and current problems

1 reference

12 December 2020

TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation

1 reference

12 December 2020

Novel cytokine-directed therapies for asthma.

1 reference

12 December 2020

Identification of gamma-E-antibodies as a carrier of reaginic activity

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3792

1 reference

28 August 2017

1 reference

PubMed ID

23197041